THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.1] ID: TIP-MED-000185

Vitamin B12 (Methylcobalamin / Mecobalamin & Cyanocobalamin)

Active Ingredient / Scientific Identity: Vitamin B12 • Class: Water-Soluble Neurotropic & Haematinic Vitamin (Cobalamin; Coenzyme for Methionine Synthase & Methylmalonyl-CoA Mutase)

⚖️ Compare Profile
Generic / Entity NameVitamin B12 (Methylcobalamin / Mecobalamin & Cyanocobalamin) ([10.1])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassWater-Soluble Neurotropic & Haematinic Vitamin (Cobalamin; Coenzyme for Methionine Synthas
Available Dosage FormsOral & Sublingual Tablets: 500 mcg, 1500 mcg (OD / Sustained-Release); Parenteral IM/IV Injection: 500 mcg/mL,
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Prefer Methylcobalamin (Mecobalamin) over Cyanocobalamin in Chronic Kidney Disease! (Cyanocobalamin releases a cyanide
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Vitamin B12 (Methylcobalamin / Mecobalamin & Cyanocobalamin) (TIP-MED-000185, Reference Code [10.1]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Water-Soluble Neurotropic & Haematinic Vitamin (Cobalamin; Coenzyme for Methionine Synthase & Methylmalonyl-CoA Mutase). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.1], p. 127): Nurokind / Nurokind-OD (Mankind—1500 mcg), Methycobal (Wockhardt—500 mcg, 1500 mcg), Meconerv (Micro Labs), Cobadex-CZS; Sublingual: Nurokind-Fast SL; Parenteral Injection: Methycobal 500 mcg / 1500 mcg ampoules, Neurobion Forte Inj — Strengths & Dosage Forms: Oral & Sublingual Tablets: 500 mcg, 1500 mcg (OD / Sustained-Release); Parenteral IM/IV Injection: 500 mcg/mL, 1000 mcg/mL, 1500 mcg/mL
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.1], p. 127): Nurokind / Nurokind-OD (Mankind—1500 mcg), Methycobal (Wockhardt—500 mcg, 1500 mcg), Meconerv (Micro Labs), Cobadex-CZS; Sublingual: Nurokind-Fast SL; Parenteral Injection: Methycobal 500 mcg / 1500 mcg ampoules, Neurobion Forte Inj — Strengths & Dosage Forms: Oral & Sublingual Tablets: 500 mcg, 1500 mcg (OD / Sustained-Release); Parenteral IM/IV Injection: 500 mcg/mL, 1000 mcg/mL, 1500 mcg/mL
Dosage Forms & Available Strengths:
Oral & Sublingual Tablets: 500 mcg, 1500 mcg (OD / Sustained-Release); Parenteral IM/IV Injection: 500 mcg/mL, 1000 mcg/mL, 1500 mcg/mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Water-Soluble Neurotropic & Haematinic Vitamin (Cobalamin; Coenzyme for Methionine Synthase & Methylmalonyl-CoA Mutase) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Water-Soluble Neurotropic & Haematinic Vitamin (Cobalamin; Coenzyme for Methionine Synthase & Methylmalonyl-CoA Mutase) for Vitamin B12 deficiency (dietary lacto-vegetarian deficiency, metformin-induced or chronic PPI-induced B12 malabsorption, pernicious anaemia); diabetic, alcoholic, and nutritional peripheral neuropathy (numbness, tingling, burning paresthesia); megaloblastic macrocytic anaemia; hyperhomocysteinaemia..

4. Therapeutic Indications & Evidence-Supported Uses

  • Vitamin B12 deficiency (dietary lacto-vegetarian deficiency, metformin-induced or chronic PPI-induced B12 malabsorption, pernicious anaemia)
  • diabetic, alcoholic, and nutritional peripheral neuropathy (numbness, tingling, burning paresthesia)
  • megaloblastic macrocytic anaemia
  • hyperhomocysteinaemia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Peripheral Neuropathy / Documented Oral Deficiency: Methylcobalamin 1500 mcg once daily (or 500 mcg three times daily) for 6 to 12 weeks, followed by maintenance 500–1500 mcg daily or alternate days (in chronic metformin/strict vegetarian patients). Severe Deficiency / Neurological Deficit (IM Injection): 1000–1500 mcg IM on alternate days for 5–7 doses, then weekly for 4 weeks, then monthly. Follow physician prescription.

Administration & Meal Timing: Oral tablets: With or without food (Sublingual tablets: place under tongue and allow to dissolve completely for 1–2 minutes without swallowing saliva immediately, bypassing gastric intrinsic factor requirement!). | Once daily in the morning after breakfast (morning administration avoids mild alerting/insomnia occasionally reported at night).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Prefer Methylcobalamin (Mecobalamin) over Cyanocobalamin in Chronic Kidney Disease! (Cyanocobalamin releases a cyanide moiety that is normally cleared by the kidneys and can accumulate in ESRD/dialysis patients; Methylcobalamin is already the active methylated cofactor and requires no cyanide detoxification!). Hepatic: Safe.
Elimination & Renal Adjustment:
Renal: Prefer Methylcobalamin (Mecobalamin) over Cyanocobalamin in Chronic Kidney Disease! (Cyanocobalamin releases a cyanide moiety that is normally cleared by the kidneys and can accumulate in ESRD/dialysis patients; Methylcobalamin is already the active methylated cofactor and requires no cyanide detoxification!). Hepatic: Safe.
Hepatic Impairment Considerations:
Renal: Prefer Methylcobalamin (Mecobalamin) over Cyanocobalamin in Chronic Kidney Disease! (Cyanocobalamin releases a cyanide moiety that is normally cleared by the kidneys and can accumulate in ESRD/dialysis patients; Methylcobalamin is already the active methylated cofactor and requires no cyanide detoxification!). Hepatic: Safe.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in Leber's hereditary optic neuropathy (cyanocobalamin can precipitate rapid optic atrophy!) and cobalt allergy. Diagnostic Precaution: In megaloblastic anaemia, always check both Vitamin B12 and Folic Acid—giving high-dose Folic Acid alone without Vitamin B12 corrects the blood count while allowing irreversible spinal cord damage (subacute combined degeneration) to progress!

Key Clinical Precautions: Renal: Prefer Methylcobalamin (Mecobalamin) over Cyanocobalamin in Chronic Kidney Disease! (Cyanocobalamin releases a cyanide moiety that is normally cleared by the kidneys and can accumulate in ESRD/dialysis patients; Methylcobalamin is already the active methylated cofactor and requires no cyanide detoxification!). Hepatic: Safe.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Exceptionally well tolerated (excess water-soluble B12 is excreted in urine); rare mild nausea, headache, or acneiform/rosacea-like skin eruptions with high parenteral doses.
  • Hypokalaemia during initial treatment of severe megaloblastic anaemia (rapid erythrocyte regeneration consumes extracellular potassium—monitor K+ in the first 48–72 hours!), rare anaphylaxis with parenteral injections (due to excipients/cobalt).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Metformin (decreases ileal calcium-dependent B12-Intrinsic Factor uptake), Proton Pump Inhibitors (pantoprazole, omeprazole—suppress gastric acid needed to cleave B12 from food proteins), Colchicine, Neomycin, Para-aminosalicylic acid, and Heavy Alcohol impair oral Vitamin B12 absorption! Chloramphenicol blunts haematopoietic response

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Explain why Methylcobalamin 1500 mcg (Nurokind-OD / Methycobal) is so widely prescribed in India: ~1% of an oral 1500 mcg dose (~15 mcg) absorbs by passive diffusion across the gut wall even when Intrinsic Factor or stomach acid is impaired by age, Metformin, or Pantoprazole! Protect Methylcobalamin strips and ampoules from light (photolabile—rapidly degrades if exposed to sunlight).
  • Meal & Clock Timing Instruction: Oral tablets: With or without food (Sublingual tablets: place under tongue and allow to dissolve completely for 1–2 minutes without swallowing saliva immediately, bypassing gastric intrinsic factor requirement!). (Once daily in the morning after breakfast (morning administration avoids mild alerting/insomnia occasionally reported at night).)
  • Missed Dose Protocol: Take as soon as remembered on the same day; do not double.
  • Geriatric Dispensing Pearl: Up to 40–50% of elderly Indian patients (especially vegetarians taking Metformin and PPIs) have subclinical or overt Vitamin B12 deficiency presenting as memory loss, unsteady gait, depression, or burning feet—screen and supplement proactively.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral & Sublingual Tablets: 500 mcg, 1500 mcg (OD / Sustained-Release); Parenteral IM/IV Injection: 500 mcg/mL, 1000 mcg/mL, 1500 mcg/mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.1] (p. 127)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.